Inspired Banking: Connecting with Your Customers Through Self-Service Banking

The advent of the pandemic changed a plethora of industries. While some fell behind, others evolved to meet the changes. Keith Lennard, an industry expert for over 12 years and the VP and Head of Software at Hyosung, knows all too well how adverse events might positively impact an industry. Specifically in this case, he know show the pandemic has accelerated movements in banking. Host Tyler Kern has a candid discussion with Lennard about the changes in the banking industry and how self-service banking is evolving the game.

Before the pandemic, changes in the industry were slow-going while still moving towards mobile utilities. However, the pandemic rapidly accelerated this growth, “There has been this kind of evolution over the last couple of years of how do you really change access to money? How do you change the banking experience?” said Lennard.

Hyosung presents a different but practical solution using evolving self-service technology. The goal isn’t just to share this knowledge but to allow others the ability to connect with their customers through self-service banking.

With personal experiences changing and practical convenience becoming an astute need for many, Lennard notes this convenience shouldn’t stop there, “expectations have changed…the consumers want to bank on their terms.”

Hyosung moves from physical to digital assets while continuing to meet and exceed customer expectations around the clock. Capitalizing on the “wealth of knowledge built into the self-service device,” self-service banking technology can meet and exceed user experiences, all while providing a solid ROI that ensures customers continue to feel appreciated.

And adoption of this technology isn’t difficult when you have the right partners. That’s why Hyosung is here to help you get started. “We’ve had a lot of success doing these integrations with our customers,” said Lennard.

To learn more, visit www.hyosungamericas.com or tune into Hyosung’s Inspired Banking Series.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More